Examples of using Available data submitted in English and their translations into Bulgarian
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The CHMP reviewed the available data submitted by the Applicant.
The CHMP concluded that the following indications are supported by the available data submitted by the MAH.
The Committee considered all the available data submitted on the safety and efficacy of quetiapine.
Concerning the“decontamination of the GI tract in immune-compromised patients whencombined with an aminoglycoside”, the CHMP reviewed the available data submitted throughout this procedure.
The Committee considered all the available data submitted from efficacy and safety.
The CVMP reviewed all available data submitted by the applicant to support the use of the product in the target species pigs for the treatment of respiratory infections caused by strains of Actinobacillus pleuropneumoniae and Pasteurella multocida susceptible to florfenicol at the dose of 22.5 mg florfenicol/kg body weight given by intramuscular administration as a single injection;
The Committee considered all the available data submitted by the MAHs.
The Committee reviewed the available data submitted in support of the new formulation of Basiron containing the new gelling agent excipient Simulgel 600 PHA;
The Committee considered the studies that heightened concerns about the increased risk of cardiovascular events associated with testosterone therapy and available data submitted from clinical trials, observational studies, meta-analyses, post-marketing data and further published data. .
The PRAC reviewed all the available data submitted with regards to the clinical safety of fusafunginecontaining products.
The Agency's recommendations are based on the results of the RODIN/PedNet study,preliminary findings from the European Haemophilia Safety Surveillance System(EUHASS) and all available data submitted from clinical trials, observational studies, published literature and quality data for Kogenate Bayer and Helixate NexGen with regards to its potential risk of inhibitor development in previously untreated patients(PUPs).
The CHMP reviewed the available data submitted by the MAHs but considered that this limited data was insufficient to conclude on the safety of meprobamate and the predictability of any associated risks.
The PRAC considered the publication of the results of the RODIN/PedNet study, the preliminary findings from the European Haemophilia Safety Surveillance System(EUHASS)registry and all available data submitted from clinical trials, observational studies, published literature and quality data for Kogenate Bayer and Helixate NexGen with regards to its potential risk of inhibitor development in previously untreated patients(PUPs).
The CVMP reviewed all available data submitted by the marketing authorisation holder, to support the indication for treatment of lice infestations caused by Linognatus vituli.
The PRAC considered results from the publication of the RODIN/PedNet study, the preliminary findings from the European Haemophilia Safety Surveillance System(EUHASS)registry and all available data submitted from clinical trials, observational studies, published literature as well as quality data for Kogenate Bayer and Helixate NexGen with regards to its potential risk of inhibitor development in previously untreated patients(PUPs) and minimally treated patients(MTPs).
The Committee considered the available data submitted in support of the use of Diclofenac Sodium Spray Gel 4% Cutaneous Spray, Solution and associated names, which included a comparison of quality aspects in relation to authorised topical diclofenac products, and literature covering pharmacokinetic(local and systemic) as well as efficacy and safety data. .
The Committee considered all the available data submitted on the safety of the methylphenidate containing products.
The PRAC reviewed all the available data submitted with regard to overdose of the paracetamol containing MR products, including intentional and accidental overdose.
The PRAC considered all the available data submitted with regards to the mechanism of action of fusafungine.
The CVMP reviewed all available data submitted by the MAH, to support the withdrawal period for chicken meat and offal at a dose rate of 20 mg/kg body weight for 4 consecutive days;
The assessment of all available data submitted by the MAH in particular the result from the PACS.
The Committee reviewed all available data submitted by the applicant to address the potential serious risk to public health, in particular concerning the contraceptive efficacy of the proposed extended dosing regimen.
The Committee considered all the available data submitted on the safety and the efficacy of modafinil-containing products.
The Committee reviewed all available data submitted by the marketing authorisation holder on the safety of Priligy in particular for the 60 mg film-coated tablets and the reported cases of syncope.
The Committee considered the results of the French SAGHE study and all available data submitted from clinical trials, registries, cohorts and safety databases in relation to the cardiovascular risk and risk of neoplasm associated with somatropin-treatment.
The Committee reviewed all available data submitted by the applicant to address the potential serious risk to public health, in particular the efficacy in respect of long-term asthma control.
The PRAC reviewed all the available data submitted with regards to the clinical efficacy and safety of fusafungine-containing products.
The Committee considered all the available data submitted on the safety and the efficacy of nimesulide-containing products for systemic use.
The Committee considered all the available data submitted on the safety of the gadolinium containing contrast agents, in relation to the risk of NSF.
The Committee reviewed all available data submitted by the marketing authorisation holder, in particular to support the efficacy of Priligy 60 mg film-coated tablets versus Priligy 30 mg filmcoated tablets.